FDA Clearance Tracker · P150013-S033
PD-L1 IHC 22C3 pharmDx
Last checked: Nov 20, 2026Latest source record: Feb 10, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Feb 10, 2026
Approved
Time to decision
134 days
Received Sep 29, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P150013-S033
- Device name
- PD-L1 IHC 22C3 pharmDx
- Applicant
- Agilent Technologies, Inc.
- Applicant location
- Santa Clara, CA
- Received
- Sep 29, 2025
- Decided
- Feb 10, 2026
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P150013
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for the PD-L1 IHC 22C3 pharmDx for expanding the indications to include use as an aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC) for treatment with KEYTRUDA® (pembrolizumab).
Source documents
Other decisions for Agilent Technologies, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- PD-L1 IHC 28-8 pharmDxPMA supplement
P150025-S018 · Decided Jul 1, 2026 · 180 days after receipt · Panel Track
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
- PD-L1 IHC 22C3 pharmDxPMA supplement
P150013-S032 · Decided Feb 11, 2026 · 187 days after receipt · Panel Track
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
P250004 · Decided Aug 15, 2025 · 178 days after receipt
Device type: Immunohistochemistry test, DNA mismatch repair (MMR) Protein assay (QNH) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.